Abstract
Objective
This study aims to assess the economic burden of prostate cancer in Iran by analyzing direct medical costs, direct non-medical costs, indirect costs, and out-of-pocket expenses associated with the disease. We conducted a cross-sectional cost-of-illness study in Khorramabad, located in western Iran, during 2023, using a prevalence-based, bottom-up approach. Data were collected from 285 prostate cancer patients at Rahimi Hospital through questionnaires, interviews, and patient records.
Results
Our study revealed that the total economic burden of prostate cancer amounted to $230,565, with an average cost of $809 per patient. Direct medical costs constituted 74% of the total burden, totaling $169,860, with therapy costs being the most significant component. Direct non-medical costs reached $13,395, while indirect costs due to productivity losses were estimated at $25,935. Out-of-pocket expenses accounted for $21,375, representing 9% of the overall costs. The substantial direct medical expenses underscore the considerable financial strain on both the healthcare system and patients. Prostate cancer imposes a significant economic burden in Iran, underscoring the urgency of enhancing insurance coverage and implementing early detection strategies to mitigate its financial impact. Standardized cost analysis methodologies and improved financial protection mechanisms are essential for alleviating the economic strain on patients and the healthcare system.